1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial
Trade Name: DEPO-MEDROL
Chemical Family: Glucocorticoid

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used as anti-inflammatory

Details of the Supplier of the Safety Data Sheet
Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture
GHS - Classification
Reproductive Toxicity: Category 1A
Specific target organ systemic toxicity (repeated exposure): Category 2

EU Classification:
EU Indication of danger: Toxic to reproduction: Category 1

EU Risk Phrases: R61 - May cause harm to the unborn child.

Label Elements

Other Hazards
No data available

Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylprednisolone Acetate</td>
<td>53-36-1</td>
<td>200-171-3</td>
<td>T;48/22-R61</td>
<td>Repr. 1A,H360D; STOT RE 2,H373</td>
<td>4-8</td>
</tr>
<tr>
<td>Myristyl-gamma-picolinium chloride</td>
<td>2748-88-1</td>
<td>220-387-1</td>
<td>Xn;R22</td>
<td>Acute Tox. 3 (H301)</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Hydrochloric Acid</td>
<td>7647-01-0</td>
<td>231-595-7</td>
<td>T; R23 C; R35</td>
<td>STOT SE 3 (H335) Skin Corr. 1A (H314) Press. Gas Acute Tox. 3 (H331)</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Water for injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Polyethylene glycol</td>
<td>25322-68-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:  
* Proprietary  
** to adjust pH  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:  
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:  
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion:  
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:  
Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:  
For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure:  
None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:  
None
5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: May include oxides of carbon.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Releases to the environment should be avoided.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Methylprednisolone Acetate
Pfizer OEL TWA-8 Hr: 4µg/m³, Skin

Sodium chloride
Latvia OEL - TWA 5 mg/m³
Lithuania OEL - TWA 5 mg/m³

Hydrochloric Acid
ACGIH Ceiling Threshold Limit: 2 ppm
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Country</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia PEAK</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>7.5 mg/m³</td>
</tr>
<tr>
<td>Austria OEL - MAKs</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>8.0 mg/m³</td>
</tr>
<tr>
<td></td>
<td>5 ppm</td>
</tr>
<tr>
<td>Cyprus OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Germany - TRGS 900 - TWAs</td>
<td>2 ppm</td>
</tr>
<tr>
<td></td>
<td>3 mg/m³</td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>2 ppm</td>
</tr>
<tr>
<td></td>
<td>3.0 mg/m³</td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>7 mg/m³</td>
</tr>
<tr>
<td>Hungary OEL - TWA</td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Italy OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Japan - OELs - Ceilings</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>7.5 mg/m³</td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Lithuania OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Luxembourg OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Malta OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Netherlands OEL - TWA</td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Poland OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Romania OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8.0 mg/m³</td>
</tr>
<tr>
<td>Slovenia OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>5 ppm</td>
</tr>
<tr>
<td></td>
<td>7.6 mg/m³</td>
</tr>
<tr>
<td>Switzerland OEL - TWAs</td>
<td>2 ppm</td>
</tr>
<tr>
<td></td>
<td>3.0 mg/m³</td>
</tr>
<tr>
<td>Vietnam OEL - TWAs</td>
<td>5 mg/m³</td>
</tr>
</tbody>
</table>

Polyethylene glycol
<table>
<thead>
<tr>
<th>Country</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria OEL - MAKs</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Germany - TRGS 900 - TWAs</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td></td>
<td>average molecular weight 200-600</td>
</tr>
</tbody>
</table>
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Slovene OEL - TWA</td>
<td>1000 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Switzerland OEL - TWAs</td>
<td>1000 ppm</td>
<td></td>
</tr>
</tbody>
</table>

**Analytical Method:** Analytical method available for methylprednisolone. Contact Pfizer Inc for further information.

**Exposure Controls:**

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits.

**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Suspension</th>
<th>Color:</th>
<th>White</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available</td>
<td>Odor Threshold:</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Solvent Solubility:</th>
<th>No data available</th>
<th>Water Solubility:</th>
<th>No data available</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH:</td>
<td>3.5 to 7.0</td>
<td>Melting/Freezing Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
<td>Partition Coefficient: (Method, pH, Endpoint, Value)</td>
<td>Methylprednisolone Predicted 7.4 Log D 1.99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Polyethylene glycol No data available</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Methylprednisolone Acetate No data available</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Water for injection No data available</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sodium chloride No data available</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Myristyl-gamma-picolinium chloride Predicted 7.4 Log D 1.30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hydrochloric Acid No data available</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sodium hydroxide No data available</td>
<td></td>
</tr>
</tbody>
</table>

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available
SAFETY DATA SHEET

Material Name: Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial
Revision date: 18-Feb-2014

Viscosity: No data available

Flammability:
- Autoignition Temperature (Solid) (°C): No data available
- Flammability (Solids): No data available
- Flash Point (Liquid) (°C): No data available
- Upper Explosive Limits (Liquid) (% by Vol.): No data available
- Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
- Oxidizing Properties: No data available
- Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
- Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
- Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients. The information included in this section describes the potential hazards of various forms of the active ingredient.
Short Term: May be harmful if absorbed through the skin.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on developing fetus and blood and blood forming organs
Known Clinical Effects: Adverse clinical reactions include the development of hypersensitivity and/or irritation leading to rashes, itching, and burning. Clinical use has resulted in hormonal alterations. Clinical use has resulted in changes in electrolytes and/or blood chemistry changes.

Acute Toxicity: (Species, Route, End Point, Dose)

Methylprednisolone
- Rat Oral LD50 > 2000 mg/kg
- Mouse Oral LD50 > 450mg/kg
- Rat Intraperitoneal LD50 1000mg/kg
- Mouse Intraperitoneal LD50 1409mg/kg
- Rat Subcutaneous LD50 > 3000mg/kg

Methylprednisolone Acetate
- Rat Oral LD50 > 10,000 mg/kg
- Mouse Sub-tenon injection (eye) LD50 > 1,409mg/kg
- Rat Subcutaneous LD50 265mg/kg

Sodium chloride
- Rat Oral LD50 3000 mg/kg
- Mouse Oral LD50 4000 mg/kg
11. TOXICOLOGICAL INFORMATION

Myristyl-gamma-picolinium chloride
<table>
<thead>
<tr>
<th>Rat</th>
<th>Oral LD 50 250 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Para-periosteal LD50 30mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>Intraperitoneal LD50 7500ug/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>Subcutaneous LD50 200mg/kg</td>
</tr>
</tbody>
</table>

Sodium hydroxide
| Mouse | IP LD50 40 mg/kg |

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Methylprednisolone
- Skin Irritation Rabbit No effect
- Eye Irritation Rabbit No effect
- Skin Sensitization - GPMT Guinea Pig No effect

Polyethylene glycol
- Eye Irritation Rabbit Mild
- Skin Irritation Rabbit Mild

Methylprednisolone Acetate
- Eye Irritation Rabbit No effect
- Skin Irritation Rabbit No effect

Sodium chloride
- Eye Irritation Rabbit Moderate
- Skin Irritation Rabbit Mild

Hydrochloric Acid
- Skin Irritation Severe
- Eye Irritation Severe

Sodium hydroxide
- Eye Irritation Rabbit Severe
- Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Methylprednisolone
- 42 Day(s) Dog Oral 167 µg/kg/day LOAEL Adrenal gland
- 6 Week(s) Rat Subcutaneous 500 µg/kg/day LOAEL None identified
- 14 Week(s) Rat Subcutaneous 0.4 µg/kg/day NOAEL Blood forming organs, Adrenal gland
- 52 Week(s) Rat Subcutaneous 4 µg/kg/day NOAEL Blood forming organs Adrenal gland

Myristyl-gamma-picolinium chloride
- 60 Day(s) Rat Oral 2400 mg/kg Death
11. TOXICOLOGICAL INFORMATION

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

**Methylprednisolone**
- Reproductive & Fertility Rat Subcutaneous 0.004 mg/kg/day NOAEL Paternal toxicity
- Reproductive & Fertility Rat Subcutaneous 0.02 mg/kg/day LOAEL Fetotoxicity
- Embryo / Fetal Development Rat Subcutaneous 1.0 mg/kg/day LOAEL Fetotoxicity, Teratogenic
- Embryo / Fetal Development Mouse Intramuscular 330 mg/kg/day LOAEL Teratogenic
- Embryo / Fetal Development Rabbit Intramuscular 0.1 mg/kg/day LOAEL Teratogenic

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

**Methylprednisolone**
- Bacterial Mutagenicity (Ames) *Salmonella* Negative
- Unscheduled DNA Synthesis Rat Hepatocyte Negative
- Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative
- Direct DNA Interaction Negative

**Methylprednisolone Acetate**
- Direct DNA Interaction Not applicable Negative

In Vitro Cytogenetics Not applicable Negative

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

**Hydrochloric Acid**
- IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

**Toxicity:** No data available

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:** No data available

**Partition Coefficient: (Method, pH, Endpoint, Value)**

**Methylprednisolone**
- Predicted 7.4 Log D 1.99

**Myristyl-gamma-picolinium chloride**
- Predicted 7.4 Log D 1.30

**Mobility in Soil:** No data available
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A

Methylprednisolone Acetate
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Australia (AICS): Present
EU EINECS/ELINCS List: 200-171-3

Myristyl-gamma-picolinium chloride
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
EU EINECS/ELINCS List: 220-387-1

Sodium chloride
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Substance</th>
<th>Regulation</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyethylene glycol</td>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td></td>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td></td>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td></td>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td></td>
<td>REACH - Annex IV - Exemptions from the obligations of Register:</td>
<td>Present</td>
</tr>
<tr>
<td></td>
<td>EU EINECS/ELINCS List</td>
<td>231-791-2</td>
</tr>
<tr>
<td>Hydrochloric Acid</td>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>1.0 %</td>
</tr>
<tr>
<td></td>
<td>CERCLA/SARA Hazardous Substances</td>
<td>5000 lb</td>
</tr>
<tr>
<td></td>
<td>and their Reportable Quantities:</td>
<td>2270 kg</td>
</tr>
<tr>
<td></td>
<td>CERCLA/SARA - Section 302 Extremely Hazardous TPQs</td>
<td>500 lb</td>
</tr>
<tr>
<td></td>
<td>CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs</td>
<td>5000 lb</td>
</tr>
<tr>
<td></td>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td></td>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td></td>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td></td>
<td>Standard for the Uniform Scheduling for Drugs and Poisons:</td>
<td>Schedule 6</td>
</tr>
<tr>
<td></td>
<td>EU EINECS/ELINCS List</td>
<td>231-595-7</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1A; H360D - May damage the unborn child
Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure if swallowed
Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation
Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage
Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled
SAFETY DATA SHEET

Material Name: Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial
Revision date: 18-Feb-2014

T - Toxic
C - Corrosive
Xn - Harmful

R61 - May cause harm to the unborn child.
R23 - Toxic by inhalation.
R35 - Causes severe burns.
R22 - Harmful if swallowed.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 9 - Physical and Chemical Properties. Updated Section 11 - Toxicology Information.

Revision date: 18-Feb-2014
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet